SuperworthNRC Health NRC
- Market cap
- $485.1M
- PE
- 87.7×
- 10y median 35.1×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 3.5×
- EV/EBIT
- 38.8×
- Revenue, 12 months
- $140M
- −0% on a year ago
- Net margin
- 4.2%
- Free cash flow yield
- 4.5%
NRC Health trades at 87.7× trailing earnings, pricier than 100% of the last ten years. Revenue was $140M over the last twelve months, down 0% on a year earlier with a 4% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $37.9M+1% | $38M−0% | $35.3M−3% | $35M−3% | $35.8M−6% | $36.9M−3% | $33.6M−5% | $34M−3% | $34.6M−3% | $35.2M−5% | $34.8M+4% | $35.4M+4% | |
| SG&A | $11.8M+10% | $11.1M+5% | $11.3M−5% | $11.2M−6% | $11M−7% | $11.5M+4% | $10.4M−8% | $17.7M+58% | $12.3M+12% | $14.4M+26% | $13.4M+30% | $22.9M+29% |
| $10M−10% | $11.7M−4% | $8.8M−3% | $8.9M−5% | $8M−20% | $9.6M−18% | $8.6M−2% | $1.6M−82% | $7.7M−3% | $4.7M−51% | $5.6M−35% | −$3.2M | |
| Interest expense | $160K−44% | $268K−6% | $605K+151% | $555K+189% | $706K+341% | $729K+172% | $899K+49% | $1M+86% | $1.5M+107% | $1.4M+88% | $1.3M+40% | $1.3M+28% |
| Pre-tax income | $10M−7% | $11.5M+21% | $8.2M−9% | $8.3M−12% | $7.3M−27% | $8.9M−23% | $7.7M−6% | $581K−93% | $6.3M−14% | $3.3M−63% | $4.4M−43% | −$4.5M |
| $2.2M−15% | $2.6M−8% | $1.8M−10% | $2.1M−1% | $1.6M−26% | $2.3M−11% | $1.9M+6% | $687K−68% | $2.2M+34% | $1.5M−37% | $1.2M−40% | −$1.3M | |
| Net income | $7.9M−5% | $8.9M+33% | $6.4M−9% | $6.2M−15% | $5.7M−28% | $6.6M−26% | $5.8M−9% | −$106K | $4.1M−28% | $1.8M−73% | $3.2M−44% | −$3.3M+2997% |
| $0.32−3% | $0.36+33% | $0.27−4% | $0.26−10% | $0.24−25% | $0.28−22% | $0.25−7% | −$0.01 | $0.18−25% | $0.08−71% | $0.14−44% | −$0.15+1400% | |
| 24.7M−1% | 24.5M−1% | 24M−3% | 23.9M−3% | 23.7M−4% | 23.4M−5% | 23M−4% | 22.7M−5% | 22.1M−7% | 21.8M−7% | 21.9M−5% | 22M−3% |
EPS, diluted: 16 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 16 periods, Q4 FY10 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Diagnostics & Research nearest NRC Health's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| NRCNRC Health | $485.1M | 87.7× | 35.1× | 3.5× | −0% | 4.2% | |
| ICCCImmucell | $93.1M | 128× | 44.0× | 3.0× | +8% | 2.6% | |
| CDNACareDx | $3.6B | 33.4× | 19.1× | 7.8× | +34% | 24.2% | |
| VCYTVeracyte | $3.9B | 34.2× | 66.8× | 6.9× | +17% | 20.4% | |
| Peer median | $3.6B | 34.2× | 44.0× | 6.9× | +17% | 20.4% |
More on NRC Health
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .